Showing results (591-600 of 610) with videos related to

Sort By:
Pageof 61
NPJ Precision Oncology|March 2, 2022
Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trialA S Mansfield, Z Wei, R Mehra, et al.
Cancer Discovery|February 28, 2018
Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived XenograftsBenjamin J Drapkin, Julie George, Camilla L Christensen, et al.
Antimicrobial Agents and Chemotherapy|October 13, 2020
Comparison of Proteomic Responses as Global Approach to Antibiotic Mechanism of Action ElucidationChristoph H R Senges, Jennifer J Stepanek, Michaela Wenzel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 11, 2011
Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practiceL V Sequist, R S Heist, A T Shaw, et al.
The New England Journal of Medicine|October 29, 2010
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancerEunice L Kwak, Yung-Jue Bang, D Ross Camidge, et al.
Cancer Discovery|February 11, 2017
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)Alexander Drilon, Salvatore Siena, Sai-Hong Ignatius Ou, et al.
The Lancet. Oncology|December 16, 2019
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trialsAlexander Drilon, Salvatore Siena, Rafal Dziadziuszko, et al.
Philosophical Transactions. Series A, Mathematical, Physical, and Engineering Sciences|December 6, 2021
Isotopic signatures of methane emissions from tropical fires, agriculture and wetlands: the MOYA and ZWAMPS flights, Euan G Nisbet, Grant Allen, et al.
The Lancet. Oncology|December 16, 2019
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trialsRobert C Doebele, Alexander Drilon, Luis Paz-Ares, et al.
Nature|July 5, 2023
Therapy-induced APOBEC3A drives evolution of persistent cancer cellsHideko Isozaki, Ramin Sakhtemani, Ammal Abbasi, et al.
Pageof 61